CFAR ANNUAL HIV RESEARCH DAY

	Hgenaa	
We	dnesday, December 6, 2017	,

Time	Торіс	Speaker		
9:00-9:05 AM	Welcome	Davey Smith, MD, MAS		
9:05-10:05 AM	Opening Address	Jamila K. Stockman, PhD, MPH		
	Session 1: Moderator - Sara Gianella Weibel, MD			
10:05-10:25 AM	Epidemiologic study to evaluate artemisinin resistance in hospitalized patients with severe malaria in Maputo, Mozambique	Lucia Chambal, MD		
10:25-10:45 AM	Predictors of pulmonary Kaposi's sarcoma in Maputo Central Hospital: preliminary results	José Sousa, MD		
10:45-11:05 AM	Beyond HIV: A qualitative exploration of factors impacting women's engagement in HIV treatment	Ava Nicole, BS		
11:05-11:20 AM	BREAK			
	Session 2: Moderator - Natasha Martin, DPhil			
11:20-11:40 AM	Psychosocial syndemics and barriers to HIV care among out- of-care HIV-positive individuals in Tijuana, Mexico	Eileen Pitpitan, PhD		
11:40 AM-12:00 PM	Examining behavior change post-HIV+ diagnosis and possibilities for intervention in rural fishing villages of Rakai, Uganda	Erika Bonnevie, MA		
12:00-12:20 PM	Characterizing engagement in HIV testing and treatment behaviors among MSM in Mexico: results from a national web-based surveillance study	Laramie Smith, PhD		
12:20-1:00 PM	LUNCH			
1:00-2:00 PM	Keynote address: HIV in Central Asia: Multi-level interventions and implementation science to address the epidemic among people who use drugs	Nabila El-Bassel, PhD		
Session 3: Moderator - Kiyomi Tsuyuki, PhD, MPH				
2:00-2:20 PM	Higher education students are a population at risk of HIV transmission: results from a cross-sectional survey in Maputo, Mozambique	Radhika Sundararajan, MD		
2:20-2:40 PM	Identifying the partners of transgender women in HIV transmission networks for targeted interventions	Manon Ragonnet-Cronin, PhD, MSc		
2:40-3:00 PM	Phylogeographic analysis suggests gravity model of HIV transmission in Mexico	Antoine Chaillon, MD, PhD		
3:00-3:20 PM	Pretreatment HIV drug resistance spread within transmission clusters in Mexico City	Santiago Avila Ríos, PhD, MSc		
3:20-3:35 PM	Closing remarks	Douglas Richman, MD		
		Page 3		